Intended for healthcare professionals

CCBYNC Open access
Research

Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis

BMJ 2012; 344 doi: https://doi.org/10.1136/bmj.e2856 (Published 04 May 2012) Cite this as: BMJ 2012;344:e2856
  1. Judith J Prochaska, associate professor1,
  2. Joan F Hilton, professor2
  1. 1Department of Psychiatry and Center for Tobacco Control Research and Education, University of California, San Francisco, CA 94143-0984
  2. 2Department of Epidemiology and Biostatistics, University of California
  1. Correspondence to: J J Prochaska JProchaska{at}ucsf.edu
  • Accepted 21 March 2012

Abstract

Objective To examine the risk of treatment emergent, cardiovascular serious adverse events associated with varenicline use for tobacco cessation.

Design Meta-analysis comparing study effects using four summary estimates.

Data sources Medline, Cochrane Library, online clinical trials registries, and reference lists of identified articles.

Review methods We included randomised controlled trials of current tobacco users of adult age comparing use of varenicline with an inactive control and reporting adverse events. We defined treatment emergent, cardiovascular serious adverse events as occurring during drug treatment or within 30 days of discontinuation, and included any ischaemic or arrhythmic adverse cardiovascular event (myocardial infarction, unstable angina, coronary revascularisation, coronary artery disease, arrhythmias, transient ischaemic attacks, stroke, sudden death or cardiovascular related death, or congestive heart failure).

Results We identified 22 trials; all were double blinded and placebo controlled; two included participants with active cardiovascular disease and 11 enrolled participants with a history of cardiovascular disease. Rates of treatment emergent, cardiovascular serious adverse events were 0.63% (34/5431) in the varenicline groups and 0.47% (18/3801) in the placebo groups. The summary estimate for the risk difference, 0.27% (95% confidence interval −0.10 to 0.63; P=0.15), based on all 22 trials, was neither clinically nor statistically significant. For comparison, the relative risk (1.40, 0.82 to 2.39; P=0.22), Mantel-Haenszel odds ratio (1.41, 0.82 to 2.42; P=0.22), and Peto odds ratio (1.58, 0.90 to 2.76; P=0.11), all based on 14 trials with at least one event, also indicated a non-significant difference between varenicline and placebo groups.

Conclusions This meta-analysis—which included all trials published to date, focused on events occurring during drug exposure, and analysed findings using four summary estimates—found no significant increase in cardiovascular serious adverse events associated with varenicline use. For rare outcomes, summary estimates based on absolute effects are recommended and estimates based on the Peto odds ratio should be avoided.

Footnotes

  • We thank Romina Kim for assistance with data abstraction and data entry with the systematic review.

  • Contributors: JJP conceived of the study, conducted the literature search and systematic review, assisted with the analyses, and led writing of the manuscript. JFH led the data analyses and assisted with writing the manuscript. Both authors are study guarantors, and had full access to all of the data (including statistical reports and tables) in the study and can take responsibility for the integrity of the data and the accuracy of the data analysis.

  • Funding: JJP is funded by the National Institute on Drug Abuse (P50 DA09253) and the State of California Tobacco-Related Disease Research Program (17RT-0077) for the submitted work. The funding agencies had no role in the conduct of the research or preparation of the manuscript.

  • Competing interests: All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: this study received support from the National Institute on Drug Abuse and the State of California Tobacco-Related Disease Research Program; JJP is principal investigator on R01 MH083684 from the National Institute of Mental Health and an Investigator Initiated Research award from Pfizer (WS981308), and is a collaborator on R34 DA030538 from the National Institute on Drug Abuse and a Cahan Award from the Flight Attendant Medical Research Institute, all of which are tobacco control trials; JFH is coinvestigator on five randomised controlled trials funded by the National Institutes of Health and the Agency for Healthcare Research and Quality, none of which are relevant to the submitted work; JFH has had no relationship with any company that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

  • Ethical approval: Not required.

  • Data sharing: Statistical code and dataset available from the corresponding author.

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode.

View Full Text